Shares in AtriCure (NSDQ:ATRC) got a boost today after the cardiovascular company’s first-quarter numbers showed a nearly 14% top-line gain and shaved a penny off its quarterly earnings loss.
Mason, Ohio-based AtriCure posted losses of -$10.1 million, or -31¢ per share, on sales of $47.0 million for the three months ended March 31, cutting its losses by -0.3% on sales growth of 13.9% compared with Q1 2017.
Analysts on Wall Street were looking for losses per share of -27¢ on sales of $45.5 million.
“We are pleased with our first-quarter performance and meaningful progress toward completing enrollment in Converge,” president & CEO Mike Carrel said in prepared remarks. “We remain well-positioned to help treat patients suffering from atrial fibrillation through our continued investments in an innovative product pipeline, clinical data, and physician education and training.”
AtriCure said it still expects to report positive adjusted EBITDA this year on sales of $190 million to $196 million.
ATRC shares were up 13.2% to $23.35 apiece today in mid-day activity.
